Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection

Hideo Yoshida, Tomoaki Kato, David M. Levi, Arie Regev, Juan R. Madariaga, Seigo Nishida, Enrique J. Martinez, Eugene R. Schiff, Masao Omata, Andreas G. Tzakis

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Background: The aim of this study was to evaluate the efficacy of lamivudine (LAM) monoprophylaxis for patients with non-replicating hepatitis B virus (HBV) infection at orthotopic liver transplantation (OLT). Methods: Among 128 liver recipients with HBV infection between 1994 and 2004 transplanted at our institution, 60 had non-replicating HBV infection at the time of OLT. Of those, 26 patients received LAM prophylaxis (monoprophylaxis group) and 34 patients received LAM and hepatitis B immunoglobulin (HBIG) prophylaxis (combination group) after OLT. Results: Median follow-up after OLT was 67 and 54 months, for monoprophylaxis and combination groups respectively. One and five yr patient/graft survival were 96/85% and 96/80% in monoprophylaxis group, and 85/79% and 67/55% in combination group. HBV DNA was re-detected or increased >10 5 IU/mL in four patients (15%) at 20-29 month in monoprophylaxis group and six (18%) at 4-35 months in combination group. Recurrent hepatitis was seen in two patients (8%) at 27 and 45 months and monoprophylaxis group and three (9%) at 21-35 months in combination group. The rate of recurrence was not statistically different between two groups. Conclusion: LAM monoprophylaxis seemed to be effective for OLT recipients with HBV infection who had non-replicating HBV at transplantation. HBIG administration may play a less valuable role in preventing HBV recurrence in this group of patients.

Original languageEnglish (US)
Pages (from-to)166-171
Number of pages6
JournalClinical Transplantation
Issue number2
StatePublished - Mar 2007


  • Hepatitis B immunoglobulin
  • Hepatitis B virus
  • Lamivudine
  • Liver transplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology


Dive into the research topics of 'Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection'. Together they form a unique fingerprint.

Cite this